BIO vs CODX
BIO (BIO) versus Co-Diagnostics, Inc. Common Stock (CODX) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
BIO does not have a complete income-statement cache yet.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
BIO currently screens at market cap $0. CODX currently screens at market cap $31.4M.
Not investment advice. Open the BIO and CODX stock pages for the full models.
Not investment advice.